About Longeveron
Longeveron is a company based in Miami (United States) founded in 2014 by Joshua M Hare. Longeveron has raised $1.05 million across 9 funding rounds from investors including NIH, HHS and TEDCO. The company has 26 employees as of December 31, 2024. Longeveron offers products and services including Lomecel-B. Longeveron operates in a competitive market with competitors including Edesa Biotech, T3D Therapeutics, Alzheon, Vivoryon and Alchemab, among others.
- Headquarter Miami, United States
- Employees 26 as on 31 Dec, 2024
- Founders Joshua M Hare
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Longeveron Inc.
-
Annual Revenue
$2.39 M (USD)237.38as on Dec 31, 2024
-
Net Profit
-$15.97 M (USD)25.41as on Dec 31, 2024
-
EBITDA
-$15.56 M (USD)20.93as on Dec 31, 2024
-
Total Equity Funding
$1.05 M (USD)
in 9 rounds
-
Latest Funding Round
$15 M (USD), Post-IPO
Mar 12, 2026
-
Investors
NIH
& 7 more
-
Employee Count
26
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Longeveron
Longeveron is a publicly listed company on the NASDAQ with ticker symbol LGVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Longeveron
Longeveron offers a comprehensive portfolio of products and services, including Lomecel-B.
Stem cell-based treatment for heart and neurodegenerative diseases
People of Longeveron
Unlock access to complete
Unlock access to complete
Funding Insights of Longeveron
Longeveron has successfully raised a total of $1.05M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Longeveron
Longeveron has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and TEDCO.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund and startup accelerator programs focused on seed and early stage companies
|
Locked | Locked | Locked | |
|
Stem cell research startups in healthcare are funded and accelerated.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Longeveron
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Longeveron
Investment portfolio details for Longeveron
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Longeveron
Detailed financials for Longeveron
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Longeveron Comparisons
Peer comparison for Longeveron
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Longeveron
Longeveron operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Edesa Biotech, T3D Therapeutics, Alzheon, Vivoryon and Alchemab, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Topical therapeutics for dermatological and gastrointestinal diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| Locked | Locked | Locked |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| Locked | Locked | Locked |
Therapeutic agents for age-related diseases like Alzheimer's are developed.
|
|
| Locked | Locked | Locked |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
Detailed competitors of Longeveron
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Longeveron
Complete news archive for Longeveron
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Longeveron
Longeveron was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Longeveron is headquartered in Miami, United States. It is registered at Miami, Florida, United States.
Longeveron is a funded company, having raised a total of $1.05M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Longeveron is 26.
Annual revenue of Longeveron is $2.39M as on Dec 31, 2024.
Longeveron was founded in 2014 in Miami, United States, within the biotechnology sector focused on cellular therapies. Operations center on the development of treatments derived from culture-expanded medicinal signaling cells sourced from adult human bone marrow donors. The lead candidate, Lomecel-B, is targeted at conditions including aging frailty, Alzheimers disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.
Longeveron's top competitors include Alzheon, Alchemab and Edesa Biotech.
Longeveron offers Lomecel-B.
Yes, Longeveron is publicly traded on NASDAQ under the ticker symbol LGVN.
Longeveron has 8 investors. Key investors include NIH, HHS, TEDCO, Maryland Stem Cell Research Fund, and Coastlands Capital.
The ticker symbol of Longeveron is LGVN on NASDAQ.